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ABSTRACT S-adenosylmethionine (SAM) is an essential metabolite in all cells. SAM is the most important
biological methyl group donor and is a precursor in the synthesis of polyamines. Methionine adenosyltransferase
(MAT; EC 2.5.1.6) catalyzes the only known SAM biosynthetic reaction from methionine and ATP. In mammalian
tissues, three different forms of MAT (MAT I, MAT III and MAT II) have been identified that are the product of two
different genes (MAT1A and MAT2A). Although MAT2A is expressed in all mammalian tissues, the expression of
MAT1A is primarily restricted to adult liver. In mammals, up to 85% of all methylation reactions and as much as
48% of methionine metabolism occurs in the liver, which indicates the important role of this organ in the regulation
of blood methionine. Recent evidence indicates that not only is SAM the main biological methyl group donor and
an intermediate metabolite in methionine catabolism, but it is also an intracellular control switch that regulates
essential hepatic functions such as liver regeneration and differentiation as well as the sensitivity of this organ to
injury. Therefore, knowledge of factors that regulate the activity of MAT I/III, the specific liver enzyme, is essential
to understand how cellular SAM levels are controlled. J. Nutr. 132: 2377S–2381S, 2002.
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INTRODUCTION
Methionine adenosyltransferase (MAT; EC 2.5.1.6) is a
central metabolic enzyme that has been exceptionally well
conserved through evolution (1). MAT is the enzyme respon-
sible for the synthesis of S-adenosylmethionine (SAM) from
L-methionine and ATP in a two-step catalyzed reaction (2,3).
SAM and tripolyphosphate (PPPi) initially are formed and
remain bound to the enzyme until PPPi is hydrolyzed to
inorganic phosphate (Pi) and the pyrophosphate ion (PPi)
before product release (4). In mammalian tissues, three forms
of MAT have been identified (5,6). MAT II, primarily ex-
pressed in extrahepatic tissues and fetal liver (7,8), is a het-
erotetramer formed of catalytic 2 and regulatory  subunits
(9,10). In adult liver, MAT exists as a tetramer (MAT I) and
as a dimer (MAT III) of a single 1 subunit of 43.7 kDa
(11,12). The function of these two isoforms of MAT in the
liver has not been yet elucidated. Similar to MAT in other
tissues, the hepatic isoforms are responsible for supplying the
liver with SAM and polyamines under physiological concen-
trations of methionine. However, MAT I/III also accounts for
the catabolism of the majority of the methionine after feeding
a meal rich in protein (13,14). The regulation of this essential
hepatic enzyme may facilitate the adaptation of hepatocytes to
different metabolic conditions. In this context, it has been
shown that the elevation of serum methionine levels in rats
fed with methionine-rich diets results in increased MAT I/III
activity (15), which may contribute to the clearance of this
amino acid. However, the activity of MAT I/III is decreased in
cirrhotic patients (16,17) as well as in different experimental
models of liver injury, such as alcohol intoxication in baboons
(18) or carbontetrachloride (CCl4) (19), paracetamol (20),
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buthionine and sulfoximine (21) intoxication in rats. Under
all these conditions there is an increased production of free
radicals. Reactive oxygen and nitrogen species induce the
inactivation of MAT I/III (22,23), which may prevent an
unnecessary consumption of ATP under stress situations in
which the availability of ATP, and therefore the viability of
hepatocytes, might be compromised. Additionally, inactiva-
tion of MAT I/III would reduce hepatic SAM levels, which
might be a key factor in regulating essential hepatic functions,
such as liver regeneration, differentiation and sensitivity of
liver to injury (24,25). The factors involved in the regulation
of the activity of MAT I/III have not been completely eluci-
dated. Our interest has been focused on the investigation of
the kinetic and structural principles that govern regulation of
MAT I/III activity.
REGULATION OF MAT I/III BY FREE RADICALS
Different studies demonstrate that under oxidative/nitrosa-
tive stress, MAT I/III activity is markedly decreased. Inhibi-
tion of glutathione (reduced) (GSH) synthesis in rats by the
administration of L-buthionine-(S,R)-sulfoximine (21), a spe-
cific inhibitor of -glutamyl cysteine synthetase, or the deple-
tion of GSH levels by CCl4 treatment (19) leads to a marked
reduction of MAT I/III activity. Additionally, increased pro-
duction of nitric oxide (NO) in the liver during septic shock
or hypoxia is associated with the inactivation of hepatic MAT;
whereas inhibition of nitric oxide synthase by NG-nitro-L-
arginine methyl ester prevented MAT inactivation in response
to hypoxia (26–28). Alcoholic cirrhosis in humans, which is
accompanied by the formation of free radicals and GSH de-
pletion (29), also is associated with reduced MAT I/III activity
(16,17) and impaired methionine metabolism (30,31). The
correlation between the formation of free radicals, as well as a
depletion of GSH levels, and MAT I/III inactivation agrees
with the finding that different thiol-reacting compounds, in-
cluding fumarylacetoacetate (32), p-(cholormercuri)-benzoate
(5), oxidized glutathione (33), H2O2 (22) and NO (26),
reduce MAT activity. This evidence suggests that the redox
state of the cysteine residues plays a key role in the control of
MAT I/III activity. Although the hepatic MAT  subunit
contains 10 cysteine residues, reactive oxygen and nitrogen
species, including hydroxyl radical, NO, and peroxynitrite
inactivate the enzyme by specific interaction only with one of
these cysteines (at position 121), which is conserved in rat,
mouse and human MAT I/III (34–36). All other known
sequences of MAT contain a glycine instead of a cysteine
residue at this position (37). Site-directed mutagenesis studies
demonstrate that the enzymatic activity of a recombinant
hepatic MAT in which cysteine 121 was substituted by a
serine residue is not decreased by H2O2 or the NO donors
S-nitroso-N-acetyl-penicillamine and S-nitrosoglutathione
(GSNO) (22,26). Furthermore, replacement of cysteine 121
by serine had no effect on MAT activity (38), indicating that
this residue is not essential for enzyme catalysis. Inactivation,
however, was not prevented by replacement by serine with any
of the other nine cysteine residues of the MAT I/III subunit
(22,26).
MAT I/III is regulated by S-nitrosylation, through a mech-
anism similar to that demonstrated for hemoglobin, cardiac
calcium release channel, and caspase 3 (39–42). MAT I and
MAT III, purified from rat liver, are inactivated in terms of
SAM synthesis by the NO donors S-nitroso-N-acetyl-penicil-
lamine (26) and GSNO (23). Substitution of cysteine 121 by
a serine residue protected MAT I/III from inactivation by
these NO donors (23,26). Incubation with 100 M GSNO
inactivates MAT I and MAT III by 70%, but whereas MAT
I incorporates one NO per subunit, in MAT III, three S-
nitroso groups per enzyme subunit are incorporated (23). Dif-
ferent accessibility to S-nitrosylation of cysteine residues lo-
cated in the interaction surfaces between dimers and therefore
not accessible in the tetrameric form might account for the
different number of the S-nitroso groups formed. Incubation
with saturating (millimolar) concentrations of GSNO leads to
the formation of eight S-nitroso groups per subunit in both
MAT isoforms (23). This finding agrees with the observation
that MAT I/III contains 10 cysteine residues, two of which
appear to form an intrasubunit disulfide bridge, probably be-
tween cysteine residues 35 and 67 (43). S-nitrosylation of both
MAT I and MAT III is reversed by millimolar concentrations
of GSH (23,26). This observation might raise doubts about the
implication of S-nitrosylation on the regulation of MAT ac-
tivity in vivo. However, intraperitoneal injection of bacterial
lipopolysaccharide into rats resulted in the accumulation of
nitrites and nitrates in serum and in the inactivation of MAT
I/III (23). The analysis of MAT III purified from lipopolysac-
charide-treated animals revealed a marked increase in the
S-nitrosylation of this enzyme in the presence of normal cel-
lular concentrations of GSH and GSSG (i.e., oxidized gluta-
thione) (23). Additionally, incubation of isolated rat hepato-
cytes with S-nitrosoglutathione monoethyl ester, an NO donor
permeable to the cell membrane, induced a five- to eightfold
increase in the hepatocyte NO content that promotes MAT
S-nitrosylation and inactivation (23). Inactivation of MAT by
S-nitrosylation induced a fivefold (80%) reduction of the
SAM content of hepatocytes within 15 min. (44), which
agrees with the observation that the half-life of hepatic SAM
is only 5 min (14). Removal of the NO donor from the
incubation media led to the denitrosylation and reactivation
of MAT and to the rapid recovery of the cellular SAM levels
(44). Reversible inactivation of MAT I/III by S-nitrosylation
then arises as a mechanism to regulate the hepatic content of
SAM. Recent data also demonstrate that incubation of iso-
lated rat hepatocytes with buthionine (S,R)-sulfoximine or its
intraperitoneal injection into rats induced a reduction of he-
patic GSH and led to the S-nitrosylation and inactivation of
hepatic MAT (45). Restoration of GSH levels in hepatocytes
and rats by treatment with the monomethyl ester of glutathi-
one reversed MAT S-nitrosylation and inactivation (45).
These observations suggest that, in the cell, MAT can exist as
two forms in equilibrium: active and inactive. This equilibrium
can be modified by alteration of the NO levels or by a deple-
tion of the intracellular GSH. Therefore, an increase of the
NO levels or a depletion of the cellular GSH will switch the
equilibrium toward the inactive, nitrosylated form, whereas a
reduction of NO content or replenishment of GSH levels
results in the denitrosylation and reactivation of MAT I/III
(Fig. 1).
As indicated above, inactivation of MAT I/III by oxidation
or nitrosylation occurs by the specific and covalent modifica-
tion of cysteine 121. According to the structural model of
hepatic MAT (22) based on the crystal structure of the Esch-
erichia coli MAT (46,47), this cysteine is located at a flexible
loop over the active-site cleft of the enzyme (46,47). This loop
can adopt two different conformations—open and closed—
and it has been proposed that in the closed conformation,
access of the substrates to the active site is prevented (37).
Nitrosylation or oxidation of cysteine 121 might induce a
conformational change in the flexible loop, making the active
site less accessible for methionine and ATP, probably by
switching the loop into the closed conformation. Alterna-
tively, it has been demonstrated that loops located over the
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active site of different enzymes play a central role in the
binding of substrates or in catalysis (48–51). Therefore, it is
worth considering that the flexible loop of MAT may be
involved in the synthesis of SAM or in the association of
methionine and/or ATP with the enzyme. According to this
work, oxidation or nitrosylation of cysteine 121 may compro-
mise the functionality of this loop, resulting in a reduced
capacity of SAM synthesis. Studies to determine which hy-
pothesis can explain these observations are in progress. As
previously mentioned, it has been proposed that protein S-
nitrosylation involves an acid-base-catalyzed nitrosothiol S-
nitrosothiol/thiol exchange reaction, in which the target cys-
teine residue is localized next to basic and acidic amino acids
that reduce the pKa of the thiol group (52). In MAT I/III,
cysteine 121 is not flanked by acidic and basic amino acids.
However, arginine residues 357 and 363 as well as aspartic acid
355 configure the tridimensional microenvironment of cys-
teine 121 (44). Replacement of these residues by serine mark-
edly reduces the capacity of GSNO to S-nitrosylate and inac-
tivate MAT (44). According to these observations, the
guanidino groups of arginine 357 and 363 may facilitate the
deprotonation of the sulfur group of cysteine 121. This will
increase the nucleophilicity of this residue (by lowering its
pKa) and consequently facilitate the nitrosylation of its sulfur
group. The function of the -carboxylic acid group of the
aspartic acid 355 may be to facilitate the protonation of
GSNO and, accordingly, facilitate the donation of the NO
group. Recognition of this topology is likely to prove useful in
identifying new targets of protein S-nitrosylation. Addition-
ally, the definition of this structural motif might facilitate the
design of new S-nitrosylation sites in proteins that are not
regulated by NO. As previously mentioned, cysteine 121 is
specific to human, rat and mouse MAT I/III, whereas all other
known sequences of this enzyme contain a glycine instead of a
cysteine residue at this position (37). However, arginine 357,
arginine 363 and aspartic acid 355, which facilitate the S-
nitrosylation of cysteine 121 in MAT I/III, are conserved in
MAT II. Replacement of glycine 120 by cysteine results in a
MAT II mutant protein that incorporates1 mol of SNO/mol
of MAT subunit and is 80% inactivated after incubation with
micromolar concentrations of GSNO. The wild-type enzyme
is not nitrosylated or inactivated after incubation with GSNO.
As is the case with the liver enzyme, the nitrosylation and
inactivation of the MAT II mutant by GSNO is reversed by 2
mM GSH (53).
MAT I/III is responsible for the catabolism of as much as
48% of the ingested methionine that is converted into SAM
at the expense of ATP. Regulation of MAT I/III by oxidation
or nitrosylation of cysteine residue 121 might have important
physiopathological consequences. With hypoxia or septic
shock, the hepatic production of NO and/or reactive oxygen
species will be increased, switching MAT into the less active
conformation. In this state, the consumption of ATP by MAT
would be reduced. This would contribute to regulating the
hepatic utilization of ATP and, therefore, to preventing nic-
otinamide adenine dinucleotide depletion and mitochondrial
de-energization during the stress imposed by either oxygen- or
nitrogen-reactive species. Indeed, overexpression of rat MAT
I/III cDNA in Chinese hamster ovary cells led to ATP and
nicotinamide adenine dinucleotide depletion and increased
the sensitivity of the cells to oxidative stress (22,54). Addi-
tionally, because SAM is associated with such hepatic func-
tions as regeneration, differentiation and liver injury
(24,25,55,56), the inactivation of MAT I/III by reactive oxy-
gen species (ROS) and NO might be a key signal in respond-
ing to injury.
HYSTERETIC BEHAVIOR OF METHIONINE
ADENOSYLTRANSFERASE. REGULATION
OF MAT ACTIVITY BY METHIONINE
CONCENTRATIONS
MAT catalyzes two consecutive reactions in vivo, the syn-
thesis of SAM and tripolyphosphate and the hydrolysis of the
latter to PPi and Pi (2). This tripolyphosphatase activity can
be studied in vitro by using tripolyphosphate as substrate.
Information about the catalytic mechanism and its regulation
can thus be obtained by using different substrates—ATP and
methionine or tripolyphosphate.
MATIII shows different responses over time with different
substrates. It is linear with tripolyphosphate, but a lag phase is
present with ATP and methionine. After the lag phase, the
kcat or turnover of the enzyme is faster than the time needed
to reach steady-state activity. This result indicates that the lag
phase is due to a slow transition, probably a change in con-
formation of the enzyme, rather than to the accumulation of a
reaction intermediate. The lag phase is not affected by SAM
and does not depend on the protein concentration, which
rules out a change in the oligomeric state of MAT. On the
other hand, the lag phase is decreased by increasing concen-
trations of substrate, suggesting induction of a conformational
change after substrate binding rather than binding to one of
the species of a pre-existing equilibrium.
Comparison of the time course of both SAM synthetase
activity and tripolyphosphatase activity indicates that they are
very similar initially, but whereas the tripolyphosphatase ac-
tivity remains the same, the SAM synthetase activity increases
with time (lag phase). This result suggests that ATP and/or
FIGURE 1 Regulation of MAT I/III by reactive oxygen species and
NO. Regulation of MAT I/III by oxidation or nitrosylation of Cys121
might have important physiopathological consequences. With hypoxia
or septic shock, the hepatic production of NO and/or reactive oxygen
species will be increased, switching MAT into the less active confor-
mation. This would contribute to regulating the hepatic utilization of
ATP and therefore to preventing nicotinamide adenine dinucleotide
depletion and mitochondrial denergization (i.e., a drop of ATP levels)
during the stress imposed by either oxygen- or nitrogen-reactive spe-
cies. Additionally, because SAM is associated with such hepatic func-
tions as regeneration, differentiation and liver injury, the inactivation of
MAT I/III by ROS and NO might be a key signal to respond to injury.
C121-S-OH/NO, oxidation or nitrosylation of cysteine residue at posi-
tion 121. GSH, glutathione (reduced); MAT, methionine adenosyltrans-
ferase; NO, nitric oxide; ROS, reactive oxygen species; SAM, S-adeno-
sylmethionine.
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methionine induces a stimulation of MAT that does not take
place with tripolyphosphate alone. To test this hypothesis,
MATIII was incubated in the presence of ATP and methio-
nine before the measurement of the tripolyphosphatase activ-
ity. Both ATP and methionine are required to stimulate the
enzyme, whereas ADP and methionine or SAM are unable to
produce any significant effect. A fourfold stimulation in en-
zyme, with a half-time of 1.5 min, is obtained. The increase in
activity, similar to the ratio of steady-state SAM synthetase to
tripolyphosphatase activities, as well as the half-time, suggest
that the stimulation of tripolyphosphatase activity and the lag
phase of SAM synthetase activity are the same process. After
stimulation, tripolyphosphatase and SAM synthetase activity
are the same. Because SAM synthetase activity measures the
rate-determining step, identical activities indicate that hydro-
lysis of tripolyphosphate is the rate-determining step. Other-
wise, tripolyphosphatase activity should be faster than SAM
synthetase activity.
As mentioned above, S-nitrosylation of MATIII inhibits
SAM synthetase activity (23). To understand the mechanism
of inhibition, characterizing the NO effect on tripolyphos-
phatase activity as well as its stimulation should be of great
value. The basal nonstimulated tripolyphosphatase activity of
MATIII is not inhibited by S-nitrosylation. Thus, NO must
affect the synthetic reaction, the stimulation process and/or
catalysis of the stimulated enzyme. The tripolyphosphatase
activity is the same when the enzyme is S-nitrosylated after
being stimulated than when it is stimulated after S-nitrosyla-
tion. In both cases the activity is intermediate between non-
stimulated and stimulated MATIII. These results indicate that
NO directly inhibits tripolyphosphatase activity of the stimu-
lated enzyme but not the stimulation process itself (57). After
S-nitrosylation, stimulated tripolyphosphatase and SAM syn-
thetase activities remain the same, indicating that NO does
not change the rate-determining step. Thus, if NO inhibits the
synthesis of SAM, this reaction still is faster than is the
hydrolysis of tripolyphosphate.
Although the concentration of ATP in hepatocytes re-
mains more or less constant, methionine levels fluctuate over
a wider range of concentrations (58). It is appealing to propose
methionine concentration in hepatocytes as a regulatory ele-
ment of MATIII activity. Supporting this proposal is the fact
that stimulation of tripolyphosphatase activity takes place in a
physiologically significant methionine concentration. To
reach 50% of stimulation, 100 M methionine is needed,
suggesting that under normal physiological concentrations,
50–80 M methionine (58), MATIII should have very low
activity. To test this hypothesis in vivo, MAT activity was
measured in intact hepatocytes as follows: two groups of hepa-
tocytes were suspended in media containing 10 or 500 M
methionine for 20 min. After this time, the cells were washed
and fresh media containing 2 mM ethionine, without methio-
nine, was added. Cell samples were taken at several intervals
to measure their S-adenosylethionine (SAE) content (44).
MAT is able to use ethionine to produce SAE (59), which is
not metabolized and accumulates in the cell. Thus, SAE
accumulation reflects MAT activity without interference by
the many enzymes that use SAM. According to the proposed
model, even though ethionine concentration is the same, it
takes longer to reach steady-state activity in cells that have
been incubated in a low methionine concentration (Fig. 2).
This indicates that MAT in the cells previously incubated
with high methionine concentration already was stimulated
when ethionine was added. The short delay observed to reach
the final activity in these cells is probably due to the time
needed for ethionine to accumulate in the hepatocytes.
The results described here can be summarized in the model
depicted in Figure 2. Under normal physiological conditions
(i.e., low methionine), a low tripolyphosphatase activity
MATIII conformation is present that is insensitive to NO.
Under these conditions, SAM concentrations in hepatocytes
are probably maintained by the small amount of MATI
present. When methionine concentration increases, such as
after a protein-rich meal, it binds together with ATP to
MATIII and induces a conformational change. The resulting
enzyme has a high tripolyphosphatase activity that is inhibited
by NO. The rate-determining step, and the one most affected
by NO, is the hydrolysis of tripolyphosphate. Once excess of
methionine is eliminated, MATIII would slowly go back to the
low-activity form (57).
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